Approval decisions are due for Jazz, Gilead and Galapagos in July, while Glaxo is preparing for a panel.
The rivals have taken different strategies with next-gen pneumococcal vaccines, which will be fighting for a blockbuster market that is Pfizer’s to lose.
The number of novel, pivotal-stage projects in big pharma pipelines has plunged – just as Covid-19 put the brakes on deal making.
Behind Lilly’s LY-CoV555 come numerous biopharma antibody projects bidding to enter clinical development.
Aduro finally runs up the white flag on Sting agonism, and becomes a listed shell for Chinook Therapeutics.
In anti-BCMA therapy Johnson & Johnson looks to have upstaged Bristol Myers Squibb again, and both companies have backups.
Merck & Co might have got off to a slow start, but now hopes to make up for lost time with multiple projects.
Close analysis of the Parp inhibitor’s pivotal prostate cancer trial raises additional questions over this week’s US approval.
Johnson & Johnson is easily the largest big pharma employer, and on certain metrics outstrips smaller rivals.